

# Anna F Farago

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/570995/publications.pdf>

Version: 2024-02-01

58  
papers

8,949  
citations

136885

32  
h-index

143943

57  
g-index

58  
all docs

58  
docs citations

58  
times ranked

10304  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of Larotrectinib in <i>TRK</i> -Fusion-Positive Cancers in Adults and Children. <i>New England Journal of Medicine</i> , 2018, 378, 731-739.	13.9	2,036
2	Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1&2 trials. <i>Lancet Oncology</i> , The, 2020, 21, 271-282.	5.1	1,034
3	<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. <i>Clinical Cancer Research</i> , 2016, 22, 4585-4593.	3.2	977
4	Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). <i>Cancer Discovery</i> , 2017, 7, 400-409.	7.7	647
5	Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. <i>Lancet Oncology</i> , The, 2020, 21, 531-540.	5.1	608
6	<i>EGFR</i> -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. <i>Journal of Clinical Oncology</i> , 2019, 37, 278-285.	0.8	286
7	Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032. <i>Journal of Thoracic Oncology</i> , 2019, 14, 237-244.	0.5	241
8	Targeting TRK family proteins in cancer. , 2017, 173, 58-66.		217
9	Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study. <i>Clinical Cancer Research</i> , 2019, 25, 6958-6966.	3.2	206
10	Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1670-1674.	0.5	197
11	Current standards for clinical management of small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, 69-79.	1.3	161
12	Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in <i>ROS1</i> -Positive Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2017, 2017, 1-13.	1.5	158
13	Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer. <i>Cancer Discovery</i> , 2019, 9, 1372-1387.	7.7	158
14	Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care. <i>Cell Reports</i> , 2017, 21, 3298-3309.	2.9	157
15	Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts. <i>Cancer Discovery</i> , 2018, 8, 600-615.	7.7	157
16	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. <i>Journal of Thoracic Oncology</i> , 2016, 11, 453-474.	0.5	156
17	Treatment with Next-Generation ALK Inhibitors Fuels Plasma <i>ALK</i> Mutation Diversity. <i>Clinical Cancer Research</i> , 2019, 25, 6662-6670.	3.2	122
18	New Approaches to SCLC Therapy: From the Laboratory to the Clinic. <i>Journal of Thoracic Oncology</i> , 2020, 15, 520-540.	0.5	119

#	ARTICLE	IF	CITATIONS
19	Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion. <i>JCO Precision Oncology</i> , 2018, 2018, 1-12.	1.5	112
20	Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E1288-96.	3.3	110
21	Identification of DHODH as a therapeutic target in small cell lung cancer. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	89
22	Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors Through Longitudinal Analysis of Circulating Tumor DNA. <i>JCO Precision Oncology</i> , 2018, 2018, 1-14.	1.5	86
23	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 1253-1263.	0.8	74
24	Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2018, 8, 1598-1613.	7.7	71
25	Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2017, 6, 550-559.	1.3	68
26	The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.. <i>Journal of Clinical Oncology</i> , 2017, 35, LBA2501-LBA2501.	0.8	63
27	Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1530-1538.	0.5	62
28	Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central nervous system tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2006-2006.	0.8	60
29	Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. <i>Nature Communications</i> , 2021, 12, 5775.	5.8	59
30	Abstract CT127: Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi). <i>Cancer Research</i> , 2019, 79, CT127-CT127.	0.4	57
31	Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor. <i>Npj Precision Oncology</i> , 2017, 1, 5.	2.3	49
32	Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C. <i>Cancer Discovery</i> , 2022, 12, 1500-1517.	7.7	49
33	Efficacy and safety of entrectinib in patients (pts) with NTRK-fusion positive (NTRK-fp) solid tumors: An updated integrated analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3605-3605.	0.8	33
34	A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. <i>Npj Precision Oncology</i> , 2021, 5, 74.	2.3	27
35	The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.. <i>Journal of Clinical Oncology</i> , 2017, 35, LBA2501-LBA2501.	0.8	27
36	Efficacy of entrectinib in patients (pts) with solid tumors and central nervous system (CNS) metastases: Integrated analysis from three clinical trials.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3017-3017.	0.8	25

#	ARTICLE	IF	CITATIONS
37	STARTRK-1: Phase 1/2a study of entrectinib, an oral Pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.. Journal of Clinical Oncology, 2015, 33, 2596-2596.	0.8	22
38	Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers. Future Oncology, 2020, 16, 417-425.	1.1	19
39	Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions. Clinical Cancer Research, 2021, 27, 1695-1705.	3.2	19
40	Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. JCO Precision Oncology, 2018, 2018, 1-13.	1.5	17
41	Unexpected Synergy Reveals New Therapeutic Strategy in SCLC. Trends in Pharmacological Sciences, 2019, 40, 295-297.	4.0	17
42	Frequency and spectrum of ROS1 resistance mutations in ROS1-positive lung cancer patients progressing on crizotinib.. Journal of Clinical Oncology, 2016, 34, 9072-9072.	0.8	12
43	Activity and safety of larotrectinib in adult patients with TRK fusion cancer: An expanded data set.. Journal of Clinical Oncology, 2020, 38, 3610-3610.	0.8	11
44	Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC. JTO Clinical and Research Reports, 2020, 1, 100074.	0.6	10
45	Larotrectinib efficacy and safety in adult TRK fusion cancer patients.. Journal of Clinical Oncology, 2019, 37, 3122-3122.	0.8	10
46	Expediting Comprehensive Molecular Analysis to Optimize Initial Treatment of Lung Cancer Patients With Minimal Smoking History. Journal of Thoracic Oncology, 2019, 14, 835-843.	0.5	9
47	Translesion DNA synthesis mediates acquired resistance to olaparib plus temozolomide in small cell lung cancer. Science Advances, 2022, 8, eabn1229.	4.7	9
48	Clonal Evolution and the Role of Serial Liquid Biopsies in a Case of Small-Cell Lung Cancerâ€“Transformed <i>EGFR</i> Mutant Nonâ€“Small-Cell Lung Cancer. JCO Precision Oncology, 2017, 1, 1-7.	1.5	8
49	The Art of Oncology: COVID-19 Era. Oncologist, 2020, 25, 997-1000.	1.9	6
50	A first-in-human study of LOXO-101, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family.. Journal of Clinical Oncology, 2015, 33, TPS2624-TPS2624.	0.8	6
51	Safety and efficacy of combination olaparib (O) and temozolomide (T) in small cell lung cancer (SCLC).. Journal of Clinical Oncology, 2018, 36, 8571-8571.	0.8	4
52	ATLANTIS: Global, randomized phase III study of lurbinectedin (L) with doxorubicin (DOX) vs. CAV or topotecan (T) in small-cell lung cancer after platinum therapy.. Journal of Clinical Oncology, 2018, 36, TPS8587-TPS8587.	0.8	4
53	Clinicopathologic features of non-small cell lung cancer (NSCLC) harboring an <i>NTRK</i> gene fusion.. Journal of Clinical Oncology, 2017, 35, 11580-11580.	0.8	2
54	Quality of life of adults and children with TRK fusion cancer treated with larotrectinib compared to the general population.. Journal of Clinical Oncology, 2020, 38, 3614-3614.	0.8	2

#	ARTICLE	IF	CITATIONS
55	Outcomes of EGFR-mutant lung adenocarcinomas (AC) that transform to small cell lung cancer (SCLC).. Journal of Clinical Oncology, 2018, 36, 8573-8573.	0.8	1
56	Clinical implementation of anchored multiplex PCR with targeted next-generation sequencing for detection of ALK, ROS1, RET and NTRK1 fusions in non-small cell lung carcinoma.. Journal of Clinical Oncology, 2015, 33, 8095-8095.	0.8	1
57	CTNI-04. ACTIVITY OF LAROTRECTINIB IN TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION CANCER PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) METASTASES. Neuro-Oncology, 2020, 22, ii41-ii42.	0.6	1
58	Phase I/II investigator-initiated study of olaparib and temozolomide in SCLC: Updated analysis and CNS outcomes.. Journal of Clinical Oncology, 2022, 40, 8565-8565.	0.8	1